Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| Sponsored by: Fisher BioServices | Published: August 31, 2015
Process improvement projects typically occur behind the scenes but often prove to have outstanding results for our clients. In this InsideAccess, you will learn about a team that has achieved unprecedented levels of shipping accuracy by documenting, tracking, and learning from their "near misses." Download InsideAccess Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!